238 related articles for article (PubMed ID: 19851209)
61. Rare form of extraovarian peritoneal serous papillary carcinoma with solitary tumor in the abdominal wall: a case report and literature review.
Matsuura T; Sugihara K; Kohmura Y; Sugimura H; Kanayama N
J Obstet Gynaecol Res; 2009 Dec; 35(6):1142-7. PubMed ID: 20144179
[TBL] [Abstract][Full Text] [Related]
62. Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin.
Hwang H; Quenneville L; Yaziji H; Gown AM
Appl Immunohistochem Mol Morphol; 2004 Jun; 12(2):122-6. PubMed ID: 15354736
[TBL] [Abstract][Full Text] [Related]
63. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
[TBL] [Abstract][Full Text] [Related]
64. Metastatic serous carcinoma presenting as inflammatory carcinoma over the breast-Report of two cases and literature review.
Panse G; Bossuyt V; Ko CJ
J Cutan Pathol; 2018 Mar; 45(3):234-239. PubMed ID: 29194708
[TBL] [Abstract][Full Text] [Related]
65. Interferon-stimulated gene, 15 kDa (ISG15) in ovarian high-grade serous carcinoma: prognostic impact and link to NF-κB pathway.
Darb-Esfahani S; Sinn BV; Rudl M; Sehouli J; Braicu I; Dietel M; Denkert C
Int J Gynecol Pathol; 2014 Jan; 33(1):16-22. PubMed ID: 24300530
[TBL] [Abstract][Full Text] [Related]
66. Cell polarity reversal in ovarian low-grade serous carcinomas and micropapillary serous borderline tumours: immunohistochemical observations.
Hui Y; Ou JJ; Sung CJ; Lawrence WD; Quddus MR
Histopathology; 2016 Nov; 69(5):892-894. PubMed ID: 27271798
[No Abstract] [Full Text] [Related]
67. Apoptotic bodies as a morphological feature in serous ovarian carcinoma: correlation with nuclear grade, Ki-67 and mitotic indices.
Brustmann H
Pathol Res Pract; 2002; 198(2):85-90. PubMed ID: 11928869
[TBL] [Abstract][Full Text] [Related]
68. Ovarian serous low malignant potential (borderline) tumor--does "micropapillary" matter?
Shih IeM
Gynecol Oncol; 2010 Apr; 117(1):1-3. PubMed ID: 20298906
[No Abstract] [Full Text] [Related]
69. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma.
Al-Hussaini M; Stockman A; Foster H; McCluggage WG
Histopathology; 2004 Feb; 44(2):109-15. PubMed ID: 14764054
[TBL] [Abstract][Full Text] [Related]
70. Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein.
Armes JE; Lourie R; de Silva M; Stamaratis G; Boyd A; Kumar B; Price G; Hyde S; Allen D; Grant P; Venter DJ
Int J Gynecol Pathol; 2005 Oct; 24(4):363-8. PubMed ID: 16175083
[TBL] [Abstract][Full Text] [Related]
71. Metastatic ovarian cancer spreading into mammary ducts mimicking an in situ component of primary breast cancer: a case report.
Maeshima Y; Osako T; Morizono H; Yunokawa M; Miyagi Y; Kikuchi M; Ueno T; Ohno S; Akiyama F
J Med Case Rep; 2021 Feb; 15(1):78. PubMed ID: 33593410
[TBL] [Abstract][Full Text] [Related]
72. Is PAX2 a reliable marker in differentiating diffuse malignant mesotheliomas of peritoneum from serous carcinomas of müllerian origin?
Gao FF; Krasinskas AM; Chivukula M
Appl Immunohistochem Mol Morphol; 2012 May; 20(3):272-6. PubMed ID: 22498671
[TBL] [Abstract][Full Text] [Related]
73. Utility of paired box gene 8 (PAX8) expression in fluid and fine-needle aspiration cytology: an immunohistochemical study of metastatic ovarian serous carcinoma.
McKnight R; Cohen C; Siddiqui MT
Cancer Cytopathol; 2010 Oct; 118(5):298-302. PubMed ID: 20572292
[TBL] [Abstract][Full Text] [Related]
74. SOX2 expression and prognostic significance in ovarian carcinoma.
Pham DL; Scheble V; Bareiss P; Fischer A; Beschorner C; Adam A; Bachmann C; Neubauer H; Boesmueller H; Kanz L; Wallwiener D; Fend F; Lengerke C; Perner S; Fehm T; Staebler A
Int J Gynecol Pathol; 2013 Jul; 32(4):358-67. PubMed ID: 23722508
[TBL] [Abstract][Full Text] [Related]
75. The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: an immunohistochemical study with comparison to renal cell carcinoma marker.
Gokden N; Gokden M; Phan DC; McKenney JK
Am J Surg Pathol; 2008 Oct; 32(10):1462-7. PubMed ID: 18685487
[TBL] [Abstract][Full Text] [Related]
76. Borderline serous papillary tumour of the testis: a case report and review of the literature.
Ibrahim AS; Li C; Al-Jafari MS
Anticancer Res; 2012 Nov; 32(11):5011-3. PubMed ID: 23155272
[TBL] [Abstract][Full Text] [Related]
77. Ovarian serous carcinoma associated with a distinct "corded and hyalinized" pattern.
Estrella JS; Wolf JK; Deavers MT
Arch Pathol Lab Med; 2013 Feb; 137(2):275-9. PubMed ID: 23368871
[TBL] [Abstract][Full Text] [Related]
78. Immunohistochemical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas.
Liu H; Shi J; Wilkerson ML; Lin F
Am J Clin Pathol; 2012 Jul; 138(1):57-64. PubMed ID: 22706858
[TBL] [Abstract][Full Text] [Related]
79. Stage IV micropapillary serous ovarian carcinoma: a report of three cases.
Kim YW; Srodon M; Bristow RE
Int J Gynecol Pathol; 2005 Jul; 24(3):235-8. PubMed ID: 15968198
[TBL] [Abstract][Full Text] [Related]
80. Malignant ascites occurs most often in patients with high-grade serous papillary ovarian cancer at initial diagnosis: a retrospective analysis of 191 women treated at Bayreuth Hospital, 2006-2015.
Krugmann J; Schwarz CL; Melcher B; Sterlacci W; Ozalinskaite A; Lermann J; Agaimy A; Vieth M
Arch Gynecol Obstet; 2019 Feb; 299(2):515-523. PubMed ID: 30415435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
